BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385-2392. [PMID: 15571587 DOI: 10.1111/j.1572-0241.2004.30186.x] [Cited by in Crossref: 327] [Cited by in F6Publishing: 251] [Article Influence: 20.4] [Reference Citation Analysis]
Number Citing Articles
1 Mitchell K, Kaul M, Clowse ME. The management of rheumatic diseases in pregnancy. Scand J Rheumatol 2010;39:99-108. [PMID: 20337545 DOI: 10.3109/03009740903449313] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
2 Longo SA, Moore RC, Canzoneri BJ, Robichaux A. Gastrointestinal Conditions during Pregnancy. Clin Colon Rectal Surg 2010;23:80-9. [PMID: 21629625 DOI: 10.1055/s-0030-1254294] [Cited by in Crossref: 37] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
3 Østensen M. Management of early aggressive rheumatoid arthritis during pregnancy and lactation. Expert Opinion on Pharmacotherapy 2009;10:1469-79. [DOI: 10.1517/14656560902980194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
4 Clowse ME. Managing contraception and pregnancy in the rheumatologic diseases. Best Pract Res Clin Rheumatol 2010;24:373-85. [PMID: 20534371 DOI: 10.1016/j.berh.2009.12.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
5 Eshuis EJ, Bemelman WA, Stokkers PC. Infliximab for the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;3:219-29. [DOI: 10.1586/egh.09.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
6 Pedersen N, Bortoli A, Duricova D, D Inca R, Panelli MR, Gisbert JP, Zoli G, López-Sanromán A, Castiglione F, Riegler G. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther. 2013;38:501-512. [PMID: 23855425 DOI: 10.1111/apt.12412] [Cited by in Crossref: 102] [Cited by in F6Publishing: 76] [Article Influence: 12.8] [Reference Citation Analysis]
7 Yildirim G, Attar R, Ficicioglu C, Karateke A, Ozkan F, Yesildaglar N. Etanercept causes regression of endometriotic implants in a rat model. Arch Gynecol Obstet 2011;283:1297-302. [DOI: 10.1007/s00404-010-1543-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
8 Elliott AB, Chakravarty EF. Immunosuppressive Medications during Pregnancy and Lactation in Women with Autoimmune Diseases. Womens Health (Lond Engl) 2010;6:431-42. [DOI: 10.2217/whe.10.24] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
9 Makol A, Wright K, Amin S. Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management. Drugs 2011;71:1973-87. [DOI: 10.2165/11596240-000000000-00000] [Cited by in Crossref: 53] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
10 Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006;131:283-311. [PMID: 16831611 DOI: 10.1053/j.gastro.2006.04.049] [Cited by in Crossref: 93] [Cited by in F6Publishing: 62] [Article Influence: 6.2] [Reference Citation Analysis]
11 Kammerlander H, Nielsen J, Knudsen T, Kjeldsen J, Friedman S, Nørgård BM. Anti–TNF-α Use During the Third Trimester of Pregnancy in Women with Moderate–severe Inflammatory Bowel Disease and the Risk of Preterm Birth and Low Birth Weight: . Inflammatory Bowel Diseases 2017;23:1916-23. [DOI: 10.1097/mib.0000000000001234] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
12 Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-melton M, Outman R, Allison JJ, Almazor MS, Bridges SL, Chatham WW, Hochberg M, Maclean C, Mikuls T, Moreland LW, O'dell J, Turkiewicz AM, Furst DE. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. [DOI: 10.1002/art.23721] [Cited by in Crossref: 986] [Cited by in F6Publishing: 701] [Article Influence: 75.8] [Reference Citation Analysis]
13 Krause ML, Makol A. Management of rheumatoid arthritis during pregnancy: challenges and solutions. Open Access Rheumatol 2016;8:23-36. [PMID: 27843367 DOI: 10.2147/OARRR.S85340] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
14 Seirafi M, de Vroey B, Amiot A, Seksik P, Roblin X, Allez M, Peyrin-biroulet L, Marteau P, Cadiot G, Laharie D, Boureille A, De Vos M, Savoye G, Rahier J, Carbonnel F, Bonaz B, Colombel J, Bouhnik Y. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther 2014;40:363-73. [DOI: 10.1111/apt.12833] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
15 Chen J, Andrews JM, Kariyawasam V, Moran N, Gounder P, Collins G, Walsh AJ, Connor S, Lee TWT, Koh CE, Chang J, Paramsothy S, Tattersall S, Lemberg DA, Radford-smith G, Lawrance IC, Mclachlan A, Moore GT, Corte C, Katelaris P, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther 2016;44:127-44. [DOI: 10.1111/apt.13670] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 9.6] [Reference Citation Analysis]
16 Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Sarto P, Hansen TS, Wewer V, Bendtsen F. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6:1212-1217; quiz 1176. [PMID: 18848503 DOI: 10.1016/j.cgh.2008.05.010] [Cited by in Crossref: 97] [Cited by in F6Publishing: 81] [Article Influence: 7.5] [Reference Citation Analysis]
17 Narula N, Al-dabbagh R, Dhillon A, Sands BE, Marshall JK. Anti-TNFα Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflammatory Bowel Diseases 2014;20:1862-9. [DOI: 10.1097/mib.0000000000000092] [Cited by in Crossref: 51] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
18 Flamant M, Bourreille A. Biothérapies et MICI: anti-TNF et nouvelles cibles thérapeutiques. La Revue de Médecine Interne 2007;28:852-61. [DOI: 10.1016/j.revmed.2007.06.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
19 Branche J, Cortot A, Bourreille A, Coffin B, de Vos M, de Saussure P, Seksik P, Marteau P, Lemann M, Colombel JF. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Inflamm Bowel Dis. 2009;15:1044-1048. [PMID: 19137604 DOI: 10.1002/ibd.20858] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
20 Takayama K, Ishikawa S, Enoki T, Kojima T, Takeuchi M. Successful treatment with infliximab for Behçet disease during pregnancy. Ocul Immunol Inflamm. 2013;21:321-323. [PMID: 23617408 DOI: 10.3109/09273948.2013.781655] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
21 Raja H, Matteson EL, Michet CJ, Smith JR, Pulido JS. Safety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding. Transl Vis Sci Technol 2012;1:6. [PMID: 24049706 DOI: 10.1167/tvst.1.2.6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
22 Uyaroglu OA, Seyhoglu E, Erden A, Kilic L, Karadag O, Akdogan A, Bilgen SA, Ertenli AI, Kiraz S, Kalyoncu U. Pregnancy outcomes in partners of male ankylosing spondylitis patients treated with anti-tumour necrosis factor-α biologics: real-life results from a single-centre cross-sectional study. Rheumatol Int 2020;40:1501-7. [PMID: 31993731 DOI: 10.1007/s00296-020-04518-3] [Reference Citation Analysis]
23 Casanova MJ, Chaparro M, Domènech E, Barreiro-de Acosta M, Bermejo F, Iglesias E, Gomollón F, Rodrigo L, Calvet X, Esteve M. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:433-440. [PMID: 23318480 DOI: 10.1038/ajg.2012.430] [Cited by in Crossref: 145] [Cited by in F6Publishing: 118] [Article Influence: 18.1] [Reference Citation Analysis]
24 Martin PL, Cornacoff JB, Treacy G, Eirikas E, Marini J, White KL, Peachee V, Hoberman A. Effects of Administration of a Monoclonal Antibody against Mouse Tumor Necrosis Factor Alpha during Pregnancy and Lactation on the Pre- and Postnatal Development of the Mouse Immune System. Int J Toxicol 2008;27:341-7. [DOI: 10.1080/10915810802368196] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
25 Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol. 2013;9:161-173; quiz 174. [PMID: 23390947 DOI: 10.1586/eci.12.103] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
26 Blonski W, Lichtenstein GR. Safety of biologic therapy: . Inflammatory Bowel Diseases 2007;13:769-96. [DOI: 10.1002/ibd.20027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
27 Caviglia R, Boškoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opinion on Drug Safety 2008;7:617-32. [DOI: 10.1517/14740338.7.5.617] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
28 Tursi A. Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn’s disease. Dig Liver Dis. 2006;38:439-440. [PMID: 16563889 DOI: 10.1016/j.dld.2006.01.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
29 Salmon JE, Alpert D. Are we coming to terms with tumor necrosis factor inhibition in pregnancy? Arthritis Rheum 2006;54:2353-5. [DOI: 10.1002/art.22027] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
30 Sato A, Naganuma M, Asakura K, Nishiwaki Y, Yajima T, Hisamatsu T, Iwao Y, Takebayashi T, Watanabe M, Hibi T. Conception outcomes and opinions about pregnancy for men with inflammatory bowel disease. J Crohns Colitis. 2010;4:183-188. [PMID: 21122503 DOI: 10.1016/j.crohns.2009.10.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
31 Fujioka K, Fukushima S, Nishida K, Iijima K, Morioka I. Intraventricular Hemorrhage Due to Coagulopathy After Vitamin K Administration in a Preterm Infant With Maternal Crohn Disease. Jpn Clin Med 2017;8:1179670717746333. [PMID: 29344001 DOI: 10.1177/1179670717746333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Pagnini C, Arseneau KO, Cominelli F. Safety considerations when using anti-TNFα therapy to treat Crohn's disease. Expert Opin Drug Saf 2015;14:31-44. [PMID: 25400161 DOI: 10.1517/14740338.2015.976610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
33 Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005;21:733-738. [PMID: 15771759 DOI: 10.1111/j.1365-2036.2005.02405.x] [Cited by in Crossref: 196] [Cited by in F6Publishing: 152] [Article Influence: 12.3] [Reference Citation Analysis]
34 Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther. 2006;23:451-463. [PMID: 16441465 DOI: 10.1111/j.1365-2036.2006.02786.x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 151] [Article Influence: 11.2] [Reference Citation Analysis]
35 Adar T, Grisaru-granovsky S, Ben Ya’acov A, Goldin E, Bar-gil Shitrit A. Pregnancy and the Immune System: General Overview and the Gastroenterological Perspective. Dig Dis Sci 2015;60:2581-9. [DOI: 10.1007/s10620-015-3683-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
36 Mahadevan U, Terdiman JP, Aron J, Jacobsohn S, Turek P. Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:395-399. [PMID: 15803031 DOI: 10.1097/01.mib.0000164023.10848.c4] [Cited by in Crossref: 89] [Cited by in F6Publishing: 22] [Article Influence: 5.6] [Reference Citation Analysis]
37 Beltagy A, Aghamajidi A, Trespidi L, Ossola W, Meroni PL. Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road. Front Pharmacol 2021;12:621247. [PMID: 34122062 DOI: 10.3389/fphar.2021.621247] [Reference Citation Analysis]
38 Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (Humira) for Crohn’s disease in pregnancy. Inflamm Bowel Dis. 2006;12:827-828. [PMID: 16917239 DOI: 10.1097/00054725-200608000-00020] [Cited by in Crossref: 92] [Cited by in F6Publishing: 67] [Article Influence: 6.1] [Reference Citation Analysis]
39 Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim YH, Lee H. [Guidelines for the management of Crohn’s disease]. Korean J Gastroenterol. 2012;59:141-179. [PMID: 22387837 DOI: 10.4166/kjg.2012.59.2.141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
40 Zelinkova Z, van der Ent C, Bruin KF, van Baalen O, Vermeulen HG, Smalbraak HJ, Ouwendijk RJ, Hoek AC, van der Werf SD, Kuipers EJ. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol. 2013;11:318-321. [PMID: 23103819 DOI: 10.1016/j.cgh.2012.10.024] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 10.2] [Reference Citation Analysis]
41 Mena-vazquez N. Safety of biologic therapies during pregnancy in women with rheumatic disease. WJR 2015;5:82. [DOI: 10.5499/wjr.v5.i2.82] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
42 Garrido E, Van Domselaar M, Morales S, López-sanromán A. Enfermedad inflamatoria intestinal y gestación. Gastroenterología y Hepatología 2010;33:517-29. [DOI: 10.1016/j.gastrohep.2009.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Ruiz V, Manubens E, Puig L. Psoriasis in pregnancy: a review (II). Actas Dermosifiliogr 2014;105:813-21. [PMID: 24314892 DOI: 10.1016/j.ad.2013.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
44 Chambers CD, Johnson DL. Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy. Birth Defects Research Part A: Clinical and Molecular Teratology 2012;94:607-11. [DOI: 10.1002/bdra.23033] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
45 Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M, Friedman S, Kane S, Manthey J, Sauberan J, Stone J, Jain R. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Am J Obstet Gynecol 2019;220:308-23. [PMID: 30948039 DOI: 10.1016/j.ajog.2019.02.027] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 12.0] [Reference Citation Analysis]
46 Alstead EM, Nelson-Piercy C. Inflammatory bowel disease in pregnancy. Gut. 2003;52:159-161. [PMID: 12524388 DOI: 10.1136/gut.52.2.159] [Cited by in Crossref: 65] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
47 Nielsen OH, Bjerrum JT, Seidelin JB, Nyberg C, Ainsworth M. Biological treatment of Crohn’s disease. Dig Dis. 2012;30 Suppl 3:121-133. [PMID: 23295703 DOI: 10.1159/000342738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
48 Jang YW, Park YS, Kim SH, Jo YJ, Jo YK, Ahn SB, Seo YS, Hong YO. A Case of Crohn's Disease Having Normal Delivery after Infliximab Treatment during Early Pregnancy. Korean J Gastroenterol 2013;61:37. [DOI: 10.4166/kjg.2013.61.1.37] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Armstrong AW, Aldredge L, Yamauchi PS. Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners. J Cutan Med Surg 2016;20:196-206. [PMID: 26712930 DOI: 10.1177/1203475415623508] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
50 Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018;48:65-77. [PMID: 29797519 DOI: 10.1111/apt.14794] [Cited by in Crossref: 66] [Cited by in F6Publishing: 47] [Article Influence: 22.0] [Reference Citation Analysis]
51 Sheth N, Greenblatt DT, Acland K, Barker J, Teixeira F. Generalized pustular psoriasis of pregnancy treated with infliximab. Clinical and Experimental Dermatology 2009;34:521-2. [DOI: 10.1111/j.1365-2230.2008.02963.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
52 Selinger CP, Leong RW, Lal S. Pregnancy related issues in inflammatory bowel disease: evidence base and patients' perspective. World J Gastroenterol 2012;18:2600-8. [PMID: 22690068 DOI: 10.3748/wjg.v18.i21.2600] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
53 Polanczyk MJ, Hopke C, Huan J, Vandenbark AA, Offner H. Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. J Neuroimmunol 2005;170:85-92. [PMID: 16253347 DOI: 10.1016/j.jneuroim.2005.08.023] [Cited by in Crossref: 130] [Cited by in F6Publishing: 114] [Article Influence: 8.1] [Reference Citation Analysis]
54 Østensen M, Förger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol. 2009;5:382-390. [PMID: 19506586 DOI: 10.1038/nrrheum.2009.103] [Cited by in Crossref: 91] [Cited by in F6Publishing: 66] [Article Influence: 7.6] [Reference Citation Analysis]
55 Reddy JG, Loftus EV. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am. 2006;35:837-855. [PMID: 17129816 DOI: 10.1016/j.gtc.2006.09.008] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 4.8] [Reference Citation Analysis]
56 D'Haens G. Anti-TNF-alpha treatment strategies: results and clinical perspectives. Gastroenterol Clin Biol 2009;33 Suppl 3:S209-16. [PMID: 20117344 DOI: 10.1016/S0399-8320(09)73156-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. Seminars in Arthritis and Rheumatism 2019;48:911-20. [DOI: 10.1016/j.semarthrit.2018.07.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
58 Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn’s disease before and after delivery. J Clin Gastroenterol. 2009;43:613-616. [PMID: 19142167 DOI: 10.1097/mcg.0b013e31817f9367] [Cited by in Crossref: 104] [Cited by in F6Publishing: 17] [Article Influence: 8.7] [Reference Citation Analysis]
59 Leung Y, Panaccione R, Ghosh S, Seow CH. Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions. Can J Gastroenterol Hepatol 2014;28:505-9. [PMID: 25101334 DOI: 10.1155/2014/967598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
60 Gaidos JK, Kane SV. Managing IBD Therapies in Pregnancy. Curr Treat Options Gastroenterol 2017;15:71-83. [PMID: 28181180 DOI: 10.1007/s11938-017-0123-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
61 Sadowski DC, Bernstein CN, Bitton A, Croitoru K, Fedorak RN, Griffiths A; CAG Crohn's Consensus Group. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol 2009;23:185-202. [PMID: 19319383 DOI: 10.1155/2009/201430] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
62 Bortoli A, Saibeni S, Tatarella M, Prada A, Beretta L, Rivolta R, Politi P, Ravelli P, Imperiali G, Colombo E. Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case-control study. J Gastroenterol Hepatol. 2007;22:542-549. [PMID: 17376049 DOI: 10.1111/j.1440-1746.2006.04754.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 3.9] [Reference Citation Analysis]
63 Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's Disease. Journal of Crohn's and Colitis 2010;4:603-5. [DOI: 10.1016/j.crohns.2010.05.001] [Cited by in Crossref: 229] [Cited by in F6Publishing: 178] [Article Influence: 20.8] [Reference Citation Analysis]
64 Ye BD, Yang S, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim Y, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Guidelines for the Management of Crohn's Disease. Intest Res 2012;10:26. [DOI: 10.5217/ir.2012.10.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
65 Vena GA, Cassano N. Anti-tumor necrosis factor therapies for psoriasis. Expert Review of Dermatology 2014;2:335-49. [DOI: 10.1586/17469872.2.3.335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
66 Plavšić I, Stimac T, Hauser G. Crohn's disease in women. Int J Womens Health 2013;5:681-8. [PMID: 24204175 DOI: 10.2147/IJWH.S38083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
67 van der Woude CJ, Kolacek S, Dotan I, Øresland T, Vermeire S, Munkholm P, Mahadevan U, Mackillop L, Dignass A; for the European Crohn's Colitis Organisation (ECCO). European evidenced-based consensus on reproduction in inflammatory bowel disease. Journal of Crohn's and Colitis 2010;4:493-510. [DOI: 10.1016/j.crohns.2010.07.004] [Cited by in Crossref: 113] [Cited by in F6Publishing: 94] [Article Influence: 10.3] [Reference Citation Analysis]
68 Mahadevan U. Fertility and pregnancy in the patient with inflammatory bowel disease. Gut. 2006;55:1198-1206. [PMID: 16849349 DOI: 10.1136/gut.2005.078097] [Cited by in Crossref: 94] [Cited by in F6Publishing: 70] [Article Influence: 6.3] [Reference Citation Analysis]
69 Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Paintaud G. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008;30:523-529. [PMID: 18641542 DOI: 10.1097/ftd.0b013e318180e300] [Cited by in Crossref: 35] [Cited by in F6Publishing: 52] [Article Influence: 2.7] [Reference Citation Analysis]
70 Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161:987-1019. [PMID: 19857207 DOI: 10.1111/j.1365-2133.2009.09505.x] [Cited by in Crossref: 308] [Cited by in F6Publishing: 226] [Article Influence: 28.0] [Reference Citation Analysis]
71 Natsumi I, Matsukawa Y, Miyagawa K, Kodaira H, Tanaka T, Horikoshi A, Takeuchi J, Takei M, Maejima M, Akimoto J. Successful childbearing in two women with rheumatoid arthritis and a history of miscarriage after etanercept treatment. Rheumatol Int 2013;33:2433-5. [DOI: 10.1007/s00296-012-2433-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
72 El Miedany Y, Palmer D. Rheumatology-led pregnancy clinic: men perspective. Clin Rheumatol 2021;40:3067-77. [PMID: 33449229 DOI: 10.1007/s10067-020-05551-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Keller J, Frederking D, Layer P. The spectrum and treatment of gastrointestinal disorders during pregnancy. Nat Rev Gastroenterol Hepatol 2008;5:430-43. [DOI: 10.1038/ncpgasthep1197] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
74 Berthelot JM, De Bandt M, Goupille P, Solau-Gervais E, Lioté F, Goeb V, Azaïs I, Martin A, Pallot-Prades B, Maugars Y. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine. 2009;76:28-34. [PMID: 19059799 DOI: 10.1016/j.jbspin.2008.04.016] [Cited by in Crossref: 83] [Cited by in F6Publishing: 66] [Article Influence: 6.4] [Reference Citation Analysis]
75 Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations. J Crohns Colitis. 2010;4:63-101. [PMID: 21122490 DOI: 10.1016/j.crohns.2009.09.009] [Cited by in Crossref: 540] [Cited by in F6Publishing: 436] [Article Influence: 45.0] [Reference Citation Analysis]
76 Saougou I, Markatseli TE, Papagoras C, Kaltsonoudis E, Voulgari PV, Drosos AA. Fertility in male patients with seronegative spondyloarthropathies treated with infliximab. Joint Bone Spine 2013;80:34-7. [PMID: 22575067 DOI: 10.1016/j.jbspin.2012.03.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
77 Cornish J, Tan E, Teare J, Teoh TG, Rai R, Clark SK, Tekkis PP. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56:830-837. [PMID: 17185356 DOI: 10.1136/gut.2006.108324] [Cited by in Crossref: 285] [Cited by in F6Publishing: 231] [Article Influence: 19.0] [Reference Citation Analysis]
78 Romanowska-Próchnicka K, Felis-Giemza A, Olesińska M, Wojdasiewicz P, Paradowska-Gorycka A, Szukiewicz D. The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding. Int J Mol Sci 2021;22:2922. [PMID: 33805757 DOI: 10.3390/ijms22062922] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
79 Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. Journal of the American Academy of Dermatology 2008;59:295-315. [DOI: 10.1016/j.jaad.2008.03.018] [Cited by in Crossref: 56] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
80 Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S. Anti-TNF therapy and pregnancy outcomes in women with inflammatory arthritis. Expert Rev Clin Immunol. 2009;5:27-34. [PMID: 20476897 DOI: 10.1586/1744666x.5.1.27] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Yarur A, Kane SV. Update on pregnancy and breastfeeding in the era of biologics. Digestive and Liver Disease 2013;45:787-94. [DOI: 10.1016/j.dld.2013.02.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
82 Kuriya B, Hernández-díaz S, Liu J, Bermas BL, Daniel G, Solomon DH. Patterns of medication use during pregnancy in rheumatoid arthritis. Arthritis Care Res 2011;63:721-8. [DOI: 10.1002/acr.20422] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
83 Theodoraki E, Orfanoudaki E, Foteinogiannopoulou K, Koutroubakis IE. Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24:1266-71. [PMID: 29718260 DOI: 10.1093/ibd/izy088] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
84 Coburn LA, Wise PE, Schwartz DA. The Successful Use of Adalimumab to Treat Active Crohn's Disease of an Ileoanal Pouch During Pregnancy. Dig Dis Sci 2006;51:2045-7. [DOI: 10.1007/s10620-006-9452-2] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 4.7] [Reference Citation Analysis]
85 Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:286-92; quiz e24. [PMID: 23200982 DOI: 10.1016/j.cgh.2012.11.011] [Cited by in Crossref: 298] [Cited by in F6Publishing: 229] [Article Influence: 33.1] [Reference Citation Analysis]
86 D’hooghe TM, Nugent NP, Cuneo S, Chai DC, Deer F, Debrock S, Kyama CM, Mihalyi A, Mwenda JM. Recombinant Human TNFRSF1A (r-hTBP1) Inhibits the Development of Endometriosis in Baboons: A Prospective, Randomized, Placebo- and Drug-Controlled Study1. Biology of Reproduction 2006;74:131-6. [DOI: 10.1095/biolreprod.105.043349] [Cited by in Crossref: 99] [Cited by in F6Publishing: 78] [Article Influence: 6.6] [Reference Citation Analysis]
87 Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR, Gottlieb AB, Koo JY, Lebwohl M, Leonardi CL, Van Voorhees AS, Bhushan R, Menter A. Research gaps in psoriasis: Opportunities for future studies. Journal of the American Academy of Dermatology 2014;70:146-67. [DOI: 10.1016/j.jaad.2013.08.042] [Cited by in Crossref: 71] [Cited by in F6Publishing: 54] [Article Influence: 10.1] [Reference Citation Analysis]
88 Dubertret L, Chimenti S, Christophers E, Daudén E, de Rie M, Griffiths CEM, Kragballe K, Ståhle M, Stingl G. Alice, Eloi, Magali and Robert: the lives of four patients with psoriasis and the therapeutic approaches of eight European experts. British Journal of Dermatology 2009;161:1-30. [DOI: 10.1111/j.1365-2133.2009.09173.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
89 Martin PL, Oneda S, Treacy G. Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am J Reprod Immunol. 2007;58:138-149. [PMID: 17631007 DOI: 10.1111/j.1600-0897.2007.00499.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 62] [Article Influence: 6.1] [Reference Citation Analysis]
90 Saha S, Wald A. Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease. Expert Opin Drug Saf. 2012;11:947-957. [PMID: 22954378 DOI: 10.1517/14740338.2012.720970] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
91 Hazes JM, Coulie PG, Geenen V, Vermeire S, Carbonnel F, Louis E, Masson P, De Keyser F. Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Rheumatology (Oxford). 2011;50:1955-1968. [PMID: 21890617 DOI: 10.1093/rheumatology/ker302] [Cited by in Crossref: 80] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
92 Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, Doria A, Rai R, Meroni P, Cetin I. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8:209. [PMID: 16712713 DOI: 10.1186/ar1957] [Cited by in Crossref: 350] [Cited by in F6Publishing: 246] [Article Influence: 23.3] [Reference Citation Analysis]
93 Correia LM, Bonilha DQ, Ramos JD, Ambrogini O, Miszputen SJ. Inflammatory bowel disease and pregnancy: report of two cases treated with infliximab and a review of the literature: . European Journal of Gastroenterology & Hepatology 2010;22:1260-4. [DOI: 10.1097/meg.0b013e328329543a] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
94 Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:823-826. [PMID: 21362710 DOI: 10.1136/ard.2010.140822] [Cited by in Crossref: 125] [Cited by in F6Publishing: 93] [Article Influence: 12.5] [Reference Citation Analysis]
95 Habal FM, Huang VW. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther. 2012;35:501-515. [PMID: 22221203 DOI: 10.1111/j.1365-2036.2011.04967.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
96 Lee KE, Jung SA, Park SH, Moon CM, Shim SY, Kim ES, Cho SJ, Kim SE, Cho KB, Yang SK. Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children's immunity. Intest Res 2019;17:237-43. [PMID: 30727711 DOI: 10.5217/ir.2018.00071] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
97 Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M, Friedman S, Kane S, Manthey J, Sauberan J, Stone J, Jain R. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Inflamm Bowel Dis 2019;25:627-41. [PMID: 30821832 DOI: 10.1093/ibd/izz037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
98 Winter R, Nørgård BM, Friedman S. Treatment of the Pregnant Patient with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22:733-744. [PMID: 26658216 DOI: 10.1097/MIB.0000000000000625] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
99 Larsen MD, Friedman S, Magnussen B, Nørgård BM. Birth Outcomes in Children Fathered by Men Treated with Anti-TNF-α Agents Before Conception. American Journal of Gastroenterology 2016;111:1608-13. [DOI: 10.1038/ajg.2016.405] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
100 Silva EFC, Baima JP, de Barros JR, Renosto FL, de Sibia CF, Saad-Hossne R, Sassaki LY. Anti-TNF Exposure during Pregnancy in Crohn's Disease Patients. Case Rep Gastroenterol 2018;12:608-16. [PMID: 30483038 DOI: 10.1159/000493921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
101 Heetun ZS, Byrnes C, Neary P, O’morain C. Review article: reproduction in the patient with inflammatory bowel disease: REVIEW: REPRODUCTION AND INFLAMMATORY BOWEL DISEASE. Alimentary Pharmacology & Therapeutics 2007;26:513-33. [DOI: 10.1111/j.1365-2036.2007.03397.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 51] [Article Influence: 5.2] [Reference Citation Analysis]
102 Shihab Z, Yeomans ND, De Cruz P. Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis.J Crohns Colitis. 2016;10:979-988. [PMID: 26755733 DOI: 10.1093/ecco-jcc/jjv234] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
103 Poturoglu S, Ormeci AC, Duman AE. Treatment of pregnant women with a diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016;7:490-502. [PMID: 27867682 DOI: 10.4292/wjgpt.v7.i4.490] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
104 Mottet C, Juillerat P, Pittet V, Gonvers J, Froehlich F, Vader J, Michetti P, Felley C. Pregnancy and Breastfeeding in Patients with Crohn’s Disease. Digestion 2008;76:149-60. [DOI: 10.1159/000111030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
105 Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol. 2009;36:635-641. [PMID: 19132789 DOI: 10.3899/jrheum.080545] [Cited by in Crossref: 195] [Cited by in F6Publishing: 135] [Article Influence: 16.3] [Reference Citation Analysis]
106 Østensen M. Therapy: are TNF inhibitors safe in pregnancy? Nat Rev Rheumatol 2009;5:184-5. [PMID: 19337279 DOI: 10.1038/nrrheum.2009.47] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
107 Osting VC, Carter JD. A safety assessment of tumor necrosis factor antagonists during pregnancy. Expert Opin Drug Saf. 2010;9:421-429. [PMID: 20367495 DOI: 10.1517/14740330903578639] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
108 Shannahan SE, Erlich JM, Peppercorn MA. Insights into the treatment of inflammatory bowel disease in pregnancy. Therap Adv Gastroenterol 2019;12:1756284819852231. [PMID: 31191713 DOI: 10.1177/1756284819852231] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
109 O’Donnell S, O’Morain C. Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment Pharmacol Ther. 2008;27:885-894. [PMID: 18284649 DOI: 10.1111/j.1365-2036.2008.03648.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
110 Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Modern Rheumatology 2014;17:451-8. [DOI: 10.3109/s10165-007-0626-3] [Cited by in Crossref: 91] [Cited by in F6Publishing: 45] [Article Influence: 13.0] [Reference Citation Analysis]
111 Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford). 2014;53:1377-1385. [PMID: 24352337 DOI: 10.1093/rheumatology/ket409] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 9.1] [Reference Citation Analysis]
112 Moscandrew M, Kane S. Inflammatory bowel diseases and management considerations: Fertility and pregnancy. Curr Gastroenterol Rep 2009;11:395-9. [DOI: 10.1007/s11894-009-0059-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
113 Huang VW, Habal FM. From conception to delivery: managing the pregnant inflammatory bowel disease patient. World J Gastroenterol 2014;20:3495-506. [PMID: 24707132 DOI: 10.3748/wjg.v20.i13.3495] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
114 Aratari A, Margagnoni G, Koch M, Papi C. Intentional infliximab use during pregnancy for severe steroid-refractory ulcerative colitis. J Crohns Colitis. 2011;5:262. [PMID: 21575893 DOI: 10.1016/j.crohns.2011.02.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
115 Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009;15:2067-73. [PMID: 19418577 DOI: 10.3748/wjg.15.2067] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 61] [Article Influence: 5.6] [Reference Citation Analysis]
116 Angelucci E, Cocco A, Viscido A, Caprilli R. Safe use of infliximab for the treatment of fistulizing Crohn’s disease during pregnancy within 3 months of conception. Inflamm Bowel Dis. 2008;14:435-436. [PMID: 18050300 DOI: 10.1002/ibd.20319] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
117 Friedman S, McElrath TF, Wolf JL. Management of fertility and pregnancy in women with inflammatory bowel disease: a practical guide. Inflamm Bowel Dis. 2013;19:2937-2948. [PMID: 23945187 DOI: 10.1097/mib.0b013e3182a0ea6f] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
118 Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Inflamm Bowel Dis. 2008;14:1736-1750. [PMID: 18626967 DOI: 10.1002/ibd.20532] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 5.6] [Reference Citation Analysis]
119 Sheibani S, Mahadevan U. Editorial: Are thiopurines and anti-TNFα agents safe to use in pregnant patients with inflammatory bowel disease? Am J Gastroenterol 2013;108:441-3. [PMID: 23459048 DOI: 10.1038/ajg.2012.436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
120 Biedermann L, Rogler G, Vavricka SR, Seibold F, Seirafi M. Pregnancy and breastfeeding in inflammatory bowel disease. Digestion. 2012;86 Suppl 1:45-54. [PMID: 23051726 DOI: 10.1159/000341941] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
121 D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007;56:725-32. [PMID: 17440187 DOI: 10.1136/gut.2006.103564] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
122 Gisbert JP, Gomollón F. Errores frecuentes en el manejo del paciente ambulatorio con enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2007;30:469-86. [DOI: 10.1157/13110491] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
123 Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, Constantin A, Fautrel B, Gaudin P, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Huet I, Jullien D, Launay O, Lemann M, Maillefert JF, Marolleau JP, Martinez V, Masson C, Morel J, Mouthon L, Pol S, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Sudre A, Tran TA, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011;78 Suppl 1:15-185. [PMID: 21703545 DOI: 10.1016/S1297-319X(11)70001-X] [Cited by in Crossref: 53] [Cited by in F6Publishing: 5] [Article Influence: 5.3] [Reference Citation Analysis]
124 Nielsen OH, Loftus EV, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med. 2013;11:174. [PMID: 23902720 DOI: 10.1186/1741-7015-11-174] [Cited by in Crossref: 80] [Cited by in F6Publishing: 67] [Article Influence: 10.0] [Reference Citation Analysis]
125 Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M, Friedman S, Kane S, Manthey J, Sauberan J, Stone J, Jain R. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology 2019;156:1508-24. [PMID: 30658060 DOI: 10.1053/j.gastro.2018.12.022] [Cited by in Crossref: 87] [Cited by in F6Publishing: 69] [Article Influence: 43.5] [Reference Citation Analysis]
126 Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf. 2014;13:1699-1708. [PMID: 25406728 DOI: 10.1517/14740338.2014.973399] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
127 Fischer-Betz RE, Schneider M. [Biologics during pregnancy and breast--feeding]. Z Rheumatol 2010;69:780-7. [PMID: 21063826 DOI: 10.1007/s00393-010-0640-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
128 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
129 Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol. 2014;43:78-84. [PMID: 24284028 DOI: 10.1016/j.reprotox.2013.11.004] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 8.3] [Reference Citation Analysis]
130 Youssef P, Kennedy D. Arthritis in pregnancy: the role and safety of biological agents. Obstet Med 2009;2:134-7. [PMID: 27579057 DOI: 10.1258/om.2009.090023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
131 Alijotas-reig J, Esteve-valverde E, Ferrer-oliveras R. Tratamiento de las gestantes con enfermedades reumáticas o autoinmunitarias sistémicas con fármacos inmunodepresores y biológicos. Medicina Clínica 2016;147:352-60. [DOI: 10.1016/j.medcli.2016.05.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
132 Park YE, Kim TO. Sexual Dysfunction and Fertility Problems in Men with Inflammatory Bowel Disease. World J Mens Health 2020;38:285-97. [PMID: 30929327 DOI: 10.5534/wjmh.190007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
133 Moens A, van Hoeve K, Humblet E, Rahier JF, Bossuyt P, Dewit S, Franchimont D, Macken E, Nijs J, Posen A, Strubbe B, Van Hootegem A, Van Moerkercke W, Vermeire S, Ferrante M; Belgian IBD Research and Development group (BIRD). Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab. J Crohns Colitis 2019;13:12-8. [PMID: 30281093 DOI: 10.1093/ecco-jcc/jjy142] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 17.0] [Reference Citation Analysis]
134 Chaudrey KH, Kane SV. Safety of Immunomodulators and Anti-TNF Therapy in Pregnancy. Curr Treat Options Gastro 2015;13:77-89. [DOI: 10.1007/s11938-014-0037-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
135 Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, Spitz B, Hoffman I, Van Steen K, Vermeire S. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011;17:1846-1854. [PMID: 21830263 DOI: 10.1002/ibd.21583] [Cited by in Crossref: 127] [Cited by in F6Publishing: 111] [Article Influence: 12.7] [Reference Citation Analysis]
136 Mahadevan U, Kane S. Use of infliximab in pregnancy. Am J Gastroenterol 2010;105:219; author reply 219-20. [PMID: 20054309 DOI: 10.1038/ajg.2009.532] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
137 Falconer H, Mwenda JM, Chai DC, Song XR, Cornillie FJ, Bergqvist A, Fried G, D'hooghe TM. Effects of anti-TNF-mAb treatment on pregnancy in baboons with induced endometriosis. Fertility and Sterility 2008;89:1537-45. [DOI: 10.1016/j.fertnstert.2007.05.062] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
138 Leung WK, Ng SC, Chow DK, Lao WC, Leung VK, Li MK, Hui YT, Ng SS, Hui AJ, Lai ST. Use of biologics for inflammatory bowel disease in Hong Kong: consensus statement. Hong Kong Med J. 2013;19:61-68. [PMID: 23378357 DOI: 10.1007/s00535-012-0673-1] [Cited by in Crossref: 74] [Cited by in F6Publishing: 61] [Article Influence: 9.3] [Reference Citation Analysis]
139 Zelinkova Z, de Haar C, de Ridder L, Pierik MJ, Kuipers EJ, Peppelenbosch MP, van der Woude CJ. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33:1053-1058. [PMID: 21366638 DOI: 10.1111/j.1365-2036.2011.04617.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 109] [Article Influence: 13.2] [Reference Citation Analysis]
140 Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106:214-223; quiz 224. [PMID: 21157441 DOI: 10.1038/ajg.2010.464] [Cited by in Crossref: 146] [Cited by in F6Publishing: 108] [Article Influence: 13.3] [Reference Citation Analysis]
141 Kane SV, Acquah LA. Placental Transport of Immunoglobulins: A Clinical Review for Gastroenterologists Who Prescribe Therapeutic Monoclonal Antibodies to Women During Conception and Pregnancy. Am J Gastroenterol 2009;104:228-33. [DOI: 10.1038/ajg.2008.71] [Cited by in Crossref: 169] [Cited by in F6Publishing: 124] [Article Influence: 13.0] [Reference Citation Analysis]
142 Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31281-7. [PMID: 32931960 DOI: 10.1016/j.cgh.2020.09.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
143 Cottone M, Criscuoli V. Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol 2011;4:227-38. [PMID: 22016584 DOI: 10.2147/CEG.S6440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
144 Rudwaleit M, Sieper J. Infliximab for the treatment of ankylosing spondylitis. Expert Opin Biol Ther 2005;5:1095-109. [PMID: 16050786 DOI: 10.1517/14712598.5.8.1095] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
145 Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res 2017;15:285-310. [PMID: 28670226 DOI: 10.5217/ir.2017.15.3.285] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
146 Deepak P, Stobaugh DJ. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease. Aliment Pharmacol Ther 2014;40:1035-43. [DOI: 10.1111/apt.12936] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
147 Kim SC, Hernandez-Diaz S. Editorial: Safety of immunosuppressive drugs in pregnant women with systemic inflammatory diseases. Arthritis Rheumatol. 2014;66:246-249. [PMID: 24504795 DOI: 10.1002/art.38258] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
148 Blonski W, Lichtenstein GR. Complications of biological therapy for inflammatory bowel diseases. Curr Opin Gastroenterol 2006;22:30-43. [PMID: 16319674 DOI: 10.1097/01.mog.0000196151.74819.8e] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
149 Østensen M, Raio L. A woman with rheumatoid arthritis whose condition did not improve during pregnancy. Nat Clin Pract Rheumatol. 2005;1:111-114; quiz 1 p. following 114. [PMID: 16932640 DOI: 10.1038/ncprheum0044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
150 Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Emery P, Keystone EC, Schiff MH, van Riel PL, Weinblatt ME, Weisman MH. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 2006;65 Suppl 3:iii2-15. [PMID: 17038465 DOI: 10.1136/ard.2006.061937] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
151 Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426-1438. [PMID: 23752881 DOI: 10.1038/ajg.2013.171] [Cited by in Crossref: 84] [Cited by in F6Publishing: 71] [Article Influence: 10.5] [Reference Citation Analysis]
152 Cush JJ. Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis 2005;64 Suppl 4:iv18-23. [PMID: 16239379 DOI: 10.1136/ard.2005.042549] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
153 Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum 2009;61:587-92. [PMID: 19404999 DOI: 10.1002/art.24462] [Cited by in Crossref: 59] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
154 Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gjertson D, Singh RR. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126:13-30. [PMID: 17916445 DOI: 10.1016/j.clim.2007.08.012] [Cited by in Crossref: 156] [Cited by in F6Publishing: 139] [Article Influence: 11.1] [Reference Citation Analysis]
155 Gaidos JK, Kane SV. Overcoming challenges of treating inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol 2016;12:871-8. [PMID: 26981845 DOI: 10.1586/1744666X.2016.1166958] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
156 Bröms G, Granath F, Ekbom A, Hellgren K, Pedersen L, Sørensen HT, Stephansson O, Kieler H. Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti–Tumor Necrosis Factor Agents During Pregnancy. Clinical Gastroenterology and Hepatology 2016;14:234-241.e5. [DOI: 10.1016/j.cgh.2015.08.039] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
157 Florea A, Job-Deslandre C. [Rheumatoid arthritis and pregnancy]. Presse Med 2008;37:1644-51. [PMID: 18819772 DOI: 10.1016/j.lpm.2008.06.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
158 Panaccione R, Fedorak RN, Aumais G, Bernard EJ, Bernstein CN, Bitton A, Croitoru K, Dieleman LA, Enns R, Feagan BG, Franchimont D, Greenberg GR, Griffiths AM, Marshall JK, Pare P, Patel S, Penner R, Render C, Seidman E, Steinhart AH. Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol 2008;22:261-72. [PMID: 18354755 DOI: 10.1155/2008/493405] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
159 Bussel JB, Giulino L, Lee S, Patel VL, Sandborg C, Stiehm ER. Update on therapeutic monoclonal antibodies. Curr Probl Pediatr Adolesc Health Care 2007;37:118-35. [PMID: 17434008 DOI: 10.1016/j.cppeds.2007.02.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
160 Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther 2017;45:941-50. [DOI: 10.1111/apt.13960] [Cited by in Crossref: 72] [Cited by in F6Publishing: 59] [Article Influence: 18.0] [Reference Citation Analysis]
161 Garip Y. Use of biologic agents for rheumatic diseases in pregnancy. WJR 2015;5:50. [DOI: 10.5499/wjr.v5.i2.50] [Reference Citation Analysis]
162 Heller MM, Wu JJ, Murase JE. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. Journal of the American Academy of Dermatology 2011;65:870. [DOI: 10.1016/j.jaad.2011.04.030] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
163 Colombel J. Efficacy and safety of adalimumab for the treatment of Crohn’s disease in adults. Expert Review of Gastroenterology & Hepatology 2014;2:163-76. [DOI: 10.1586/17474124.2.2.163] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
164 Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to Infliximab During Pregnancy: Post-Marketing Experience. Drug Saf 2020;43:147-61. [PMID: 31677004 DOI: 10.1007/s40264-019-00881-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
165 Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, De Vitis I, Guidi L, Gasbarrini A. Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol. 2009;104:1575-1586. [PMID: 19491875 DOI: 10.1038/ajg.2009.162] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
166 Lis K, Kuzawińska O, Bałkowiec-Iskra E. Tumor necrosis factor inhibitors - state of knowledge. Arch Med Sci 2014;10:1175-85. [PMID: 25624856 DOI: 10.5114/aoms.2014.47827] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 14.5] [Reference Citation Analysis]
167 de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:985-1002. [PMID: 21936033 DOI: 10.1002/ibd.21871] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
168 Bangsgaard N, Rørbye C, Skov L. Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments. Am J Clin Dermatol 2015;16:389-98. [PMID: 26149091 DOI: 10.1007/s40257-015-0137-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
169 Habal FM, Kapila V. Inflammatory bowel disease and pregnancy: evidence, uncertainty and patient decision-making. Can J Gastroenterol 2009;23:49-53. [PMID: 19172209 DOI: 10.1155/2009/531638] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
170 Mozaffari S, Abdolghaffari A, Nikfar S, Abdollahi M. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: A systematic review with meta-analysis. Hum Exp Toxicol 2015;34:445-59. [DOI: 10.1177/0960327114550882] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
171 Pham-Huy A, Sadarangani M, Huang V, Ostensen M, Castillo E, Troster SM, Vaudry W, Nguyen GC, Top KA. From mother to baby: antenatal exposure to monoclonal antibody biologics. Expert Rev Clin Immunol 2019;15:221-9. [PMID: 30570400 DOI: 10.1080/1744666X.2019.1561282] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
172 Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis. 2010;16:881-895. [PMID: 19885906 DOI: 10.1002/ibd.21154] [Cited by in Crossref: 102] [Cited by in F6Publishing: 69] [Article Influence: 9.3] [Reference Citation Analysis]
173 Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D; ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20. [PMID: 16096329 DOI: 10.1136/ard.2005.040758] [Cited by in Crossref: 228] [Cited by in F6Publishing: 162] [Article Influence: 14.3] [Reference Citation Analysis]
174 Cassina M, Fabris L, Okolicsanyi L, Gervasi MT, Memmo A, Tiboni GM, Di Gianantonio E, Clementi M. Therapy of inflammatory bowel diseases in pregnancy and lactation. Expert Opinion on Drug Safety 2009;8:695-707. [DOI: 10.1517/14740330903357463] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
175 Mountifield R, Andrews JM, Bampton P. It IS worth the effort: Patient knowledge of reproductive aspects of inflammatory bowel disease improves dramatically after a single group education session. J Crohns Colitis. 2014;8:796-801. [PMID: 24467964 DOI: 10.1016/j.crohns.2013.12.019] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
176 Bae YC, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo B, Kimball AB. Review of treatment options for psoriasis in pregnant or lactating women: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology 2012;67:459-77. [DOI: 10.1016/j.jaad.2011.07.039] [Cited by in Crossref: 73] [Cited by in F6Publishing: 43] [Article Influence: 8.1] [Reference Citation Analysis]
177 Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother 2007;8:2089-107. [PMID: 17714062 DOI: 10.1517/14656566.8.13.2089] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 4.1] [Reference Citation Analysis]
178 McConnell RA, Mahadevan U. Use of Immunomodulators and Biologics Before, During, and After Pregnancy. Inflamm Bowel Dis. 2016;22:213-223. [PMID: 26444103 DOI: 10.1097/mib.0000000000000596] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
179 Holmgren C, Esplin MS, Hamblin S, Molenda M, Simonsen S, Silver R. Evaluation of the use of anti-TNF-alpha in an LPS-induced murine model. J Reprod Immunol 2008;78:134-9. [PMID: 18433878 DOI: 10.1016/j.jri.2007.11.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
180 Mahadevan U. Pregnancy and Inflammatory Bowel Disease. Medical Clinics of North America 2010;94:53-73. [DOI: 10.1016/j.mcna.2009.08.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
181 Correia LM, Bonilha DQ, Ramos JD, Ambrogini O, Miszputen SJ. Treatment of inflammatory bowel disease and pregnancy: a review of the literature. Arq Gastroenterol 2010;47:197-201. [DOI: 10.1590/s0004-28032010000200016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
182 Blonski W, Lichtenstein GR. Safety of biologics in inflammatory bowel disease. Curr Treat Options Gastroenterol 2006;9:221-33. [PMID: 16901386 DOI: 10.1007/s11938-006-0041-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
183 Paschou S, Voulgari PV, Vrabie IG, Saougou IG, Drosos AA. Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab. J Rheumatol. 2009;36:351-354. [PMID: 19040305 DOI: 10.3899/jrheum.080554] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
184 Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan JG, Safdi M, Nissinen R, Taillard F, Sandborn WJ, Cohen RD. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol 2018;113:1678-88. [PMID: 30022113 DOI: 10.1038/s41395-018-0202-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
185 Bortoli A, Pedersen N, Duricova D, D'Inca R, Gionchetti P, Panelli MR, Ardizzone S, Sanroman AL, Gisbert JP, Arena I, Riegler G, Marrollo M, Valpiani D, Corbellini A, Segato S, Castiglione F, Munkholm P; European Crohn-Colitis Organisation (ECCO) Study Group of Epidemiologic Committee (EpiCom). Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther. 2011;34:724-734. [PMID: 21815900 DOI: 10.1111/j.1365-2036.2011.04794.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 92] [Article Influence: 10.5] [Reference Citation Analysis]
186 Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol. 2008;14:3085-3087. [PMID: 18494064 DOI: 10.3748/wjg.14.3085] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
187 Zrour-hassen S, Jguirim M, Aouam K, Korbaa W, Younes M, Bejia I, Touzi M, Bergaoui N. Sécurité des médicaments à usage rhumatologique en âge de procréation. Therapies 2010;65:465-73. [DOI: 10.2515/therapie/2010061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
188 Travassos WJ, Cheifetz AS. Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005;8:187-196. [PMID: 15913508 DOI: 10.1007/s11938-005-0011-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
189 Clowse ME. The use of anti-TNFα medications for rheumatologic disease in pregnancy. Int J Womens Health 2010;2:199-209. [PMID: 21072312 DOI: 10.2147/ijwh.s6029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
190 Robinson AA, Watson WJ, Leslie KK. Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. The Lancet Oncology 2007;8:738-43. [DOI: 10.1016/s1470-2045(07)70242-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
191 Hoxha A, Calligaro A, Di Poi E, Peccatori S, Favaro M, Del Ross T, Ramonda R, Grava C, Raffeiner B, Ravagni P, De Vita S, Ruffatti A. Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study. Joint Bone Spine 2017;84:169-73. [DOI: 10.1016/j.jbspin.2016.03.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
192 Krause ML, Amin S, Makol A. Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know. Ther Adv Musculoskelet Dis 2014;6:169-84. [PMID: 25342996 DOI: 10.1177/1759720X14551568] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
193 Wan J, Imadojemu S, Werth VP. Management of rheumatic and autoimmune blistering disease in pregnancy and postpartum. Clinics in Dermatology 2016;34:344-52. [DOI: 10.1016/j.clindermatol.2016.02.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
194 Mössner R, Reich K. Infliximab in the treatment of psoriasis. Expert Review of Dermatology 2014;1:515-26. [DOI: 10.1586/17469872.1.4.515] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
195 Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn’s disease before and after delivery. J Clin Gastroenterol. 2009;43:613-616. [PMID: 19142167 DOI: 10.10.1097/mcg.0b013e31817f9367] [Reference Citation Analysis]
196 Pinder M, Lummis K, Selinger CP. Managing inflammatory bowel disease in pregnancy: current perspectives. Clin Exp Gastroenterol 2016;9:325-35. [PMID: 27789969 DOI: 10.2147/CEG.S96676] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 2.2] [Reference Citation Analysis]
197 Shen X, Wan Q, Zhao R, Wu Y, Wang Y, Cui Y, Su X, Wu X. Inflammatory bowel diseases and the risk of adverse health outcomes: Umbrella review of meta-analyses of observational studies. Dig Liver Dis 2021;53:809-16. [PMID: 33551353 DOI: 10.1016/j.dld.2021.01.018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Androulakis I, Zavos C, Christopoulos P, Mastorakos G, Gazouli M. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease. World J Gastroenterol. 2015;21:13205-13211. [PMID: 26715803 DOI: 10.3748/wjg.v21.i47.13205] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
199 Kammerlander H, Nielsen J, Kjeldsen J, Knudsen T, Friedman S, Nørgård B. The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1011-8. [PMID: 28346274 DOI: 10.1097/MIB.0000000000001102] [Cited by in Crossref: 57] [Cited by in F6Publishing: 10] [Article Influence: 19.0] [Reference Citation Analysis]
200 Babalola O, Strober BE. Management of psoriasis in pregnancy: Treatment of cutaneous disorders of pregnancy. Dermatol Ther 2013;26:285-92. [DOI: 10.1111/dth.12073] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
201 Simon PC, Vallano A. [Anti-tumor necrosis factor-α medications and pregnancy]. Med Clin (Barc) 2013;141:257-9. [PMID: 23702347 DOI: 10.1016/j.medcli.2013.04.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
202 Vermeire S, Carbonnel F, Coulie PG, Geenen V, Hazes JM, Masson PL, De Keyser F, Louis E. Management of inflammatory bowel disease in pregnancy. J Crohns Colitis. 2012;6:811-823. [PMID: 22595185 DOI: 10.1016/j.crohns.2012.04.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
203 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn’s disease. World J Gastroenterol. 2012;18:4823-4854. [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
204 Skomsvoll JF, Wallenius M, Koksvik HS, Rødevand E, Salvesen KA, Spigset O, Kvien TK. Drug insight: Anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation. Nat Clin Pract Rheumatol. 2007;3:156-164. [PMID: 17334338 DOI: 10.1038/ncprheum0426] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
205 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 5.5] [Reference Citation Analysis]
206 Bewtra M, Lichtenstein GR. Infliximab use in Crohn’s disease. Expert Opinion on Biological Therapy 2005;5:589-99. [DOI: 10.1517/14712598.5.4.589] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
207 Picardo S, Seow CH. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy. Drugs 2019;79:1053-63. [PMID: 31183768 DOI: 10.1007/s40265-019-01141-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
208 Lioté F. Médicaments rhumatologiques autorisés pendant la grossesse. Revue du Rhumatisme 2005;72:755-60. [DOI: 10.1016/j.rhum.2005.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
209 Cao RH, Grimm MC. Pregnancy and medications in inflammatory bowel disease. Obstet Med 2021;14:4-11. [PMID: 33995565 DOI: 10.1177/1753495X20919214] [Reference Citation Analysis]
210 Mahadevan U. Pregnancy and inflammatory bowel disease. Gastroenterol Clin North Am. 2009;38:629-649. [PMID: 19913206 DOI: 10.1016/j.gtc.2009.07.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
211 Hyrich KL, Symmons DP, Watson KD, Silman AJ. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum. 2006;54:2701-2702. [PMID: 16871549 DOI: 10.1002/art.22028] [Cited by in Crossref: 80] [Cited by in F6Publishing: 60] [Article Influence: 5.3] [Reference Citation Analysis]
212 Djokanovic N, Klieger-Grossmann C, Pupco A, Koren G. Safety of infliximab use during pregnancy. Reprod Toxicol. 2011;32:93-97. [PMID: 21621603 DOI: 10.1016/j.reprotox.2011.05.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
213 Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut. 2005;54:890. [PMID: 15888806 DOI: 10.1136/gut.2005.065417] [Cited by in Crossref: 111] [Cited by in F6Publishing: 77] [Article Influence: 6.9] [Reference Citation Analysis]
214 van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsanos K, Kolacek S, Juillerat P, Mulders AG, Pedersen N. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107-124. [PMID: 25602023 DOI: 10.1093/ecco-jcc/jju006] [Cited by in Crossref: 220] [Cited by in F6Publishing: 177] [Article Influence: 44.0] [Reference Citation Analysis]
215 Stone RH, Hong J, Jeong H. Pharmacokinetics of monoclonal antibodies used for inflammatory bowel diseases in pregnant women. J Clin Toxicol 2014;4:209. [PMID: 26539323 DOI: 10.4172/2161-0495.1000209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
216 Bortlik M, Machkova N, Duricova D, Malickova K, Hrdlicka L, Lukas M, Kohout P, Shonova O, Lukas M. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study. Scand J Gastroenterol. 2013;48:951-958. [PMID: 23834232 DOI: 10.3109/00365521.2013.812141] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 5.5] [Reference Citation Analysis]
217 Doria A, Iaccarino L, Arienti S, Ghirardello A, Zampieri S, Rampudda ME, Cutolo M, Tincani A, Todesco S. Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases. Reprod Toxicol 2006;22:234-41. [PMID: 16704920 DOI: 10.1016/j.reprotox.2006.04.001] [Cited by in Crossref: 85] [Cited by in F6Publishing: 64] [Article Influence: 5.7] [Reference Citation Analysis]
218 Chaparro M, Gisbert JP. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease? Expert Opinion on Drug Safety 2014;13:1749-62. [DOI: 10.1517/14740338.2014.959489] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
219 Pucino F, Harbus PT, Goldbach-mansky R. Use of biologics in rheumatoid arthritis: Where are we going? American Journal of Health-System Pharmacy 2006;63:S19-41. [DOI: 10.2146/ajhp060365] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
220 Yiu ZZ, Griffiths CE, Warren RB. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. Br J Dermatol. 2014;171:485-491. [PMID: 24749725 DOI: 10.1111/bjd.13060] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
221 Korelitz BI. Continuing immunomodulators and biologic medications in pregnant IBD patients — Sometimes con: . Inflammatory Bowel Diseases 2007;13:1441-2. [DOI: 10.1002/ibd.20248] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
222 Habal FM, Ravindran NC. Management of inflammatory bowel disease in the pregnant patient. World J Gastroenterol. 2008;14:1326-1332. [PMID: 18322943 DOI: 10.3748/wjg.14.1326] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
223 Hagen-hurley T. Conception, fertility and pregnancy inwomen with inflammatory bowel disease. Gastrointestinal Nursing 2008;6:34-9. [DOI: 10.12968/gasn.2008.6.4.29385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
224 Ooi CJ, Makharia GK, Hilmi I, Gibson PR, Fock KM, Ahuja V, Ling KL, Lim WC, Thia KT, Wei SC, Leung WK, Koh PK, Gearry RB, Goh KL, Ouyang Q, Sollano J, Manatsathit S, de Silva HJ, Rerknimitr R, Pisespongsa P, Abu Hassan MR, Sung J, Hibi T, Boey CC, Moran N, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease. Asia-Pacific consensus statements on Crohn's disease. Part 2: Management. J Gastroenterol Hepatol. 2016;31:56-68. [PMID: 25819311 DOI: 10.1111/jgh.12958] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
225 Ali YM, Kuriya B, Orozco C, Cush JJ, Keystone EC. Can tumor necrosis factor inhibitors be safely used in pregnancy? J Rheumatol 2010;37:9-17. [PMID: 20008917 DOI: 10.3899/jrheum.090563] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
226 Kiely CJ, Subramaniam K, Platten J, Pavli P. Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis: Brief Communications. Intern Med J 2016;46:616-9. [DOI: 10.1111/imj.13057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
227 Kane S. Gender Issues in Inflammatory Bowel Disease. Womens Health (Lond Engl) 2005;1:401-7. [DOI: 10.2217/17455057.1.3.401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
228 Kwan LY, Mahadevan U. Inflammatory bowel disease and pregnancy: an update. Expert Rev Clin Immunol. 2010;6:643-657. [PMID: 20594137 DOI: 10.1586/eci.10.35] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
229 Siddiqui MAA, Scott LJ. Infliximab: A Review of its Use in Crohn???s Disease and Rheumatoid Arthritis. Drugs 2005;65:2179-208. [DOI: 10.2165/00003495-200565150-00014] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
230 Pathirana D, Ormerod A, Saiag P, Smith C, Spuls P, Nast A, Barker J, Bos J, Burmester G, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen S, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne J, Orzechowski H, Rantanen T, Reich K, Reytan N, Richards H, Thio H, van de Kerkhof P, Rzany B. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology 2009;23:1-70. [DOI: 10.1111/j.1468-3083.2009.03389.x] [Cited by in Crossref: 421] [Cited by in F6Publishing: 324] [Article Influence: 35.1] [Reference Citation Analysis]
231 Lamboglia F, Dʼincà R, Oliva L, Bertomoro P, Sturniolo GC. Patient with Severe Crohnʼs Disease Became a Father While on Methotrexate and Infliximab Therapy: . Inflammatory Bowel Diseases 2009;15:648-9. [DOI: 10.1002/ibd.20722] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
232 Chambers CD, Tutuncu ZN, Johnson D, Jones KL. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther. 2006;8:215. [PMID: 16774693 DOI: 10.1186/ar1977] [Cited by in Crossref: 58] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
233 Weatherhead S, Robson SC, Reynolds NJ. Management of psoriasis in pregnancy. BMJ 2007;334:1218-20. [PMID: 17556479 DOI: 10.1136/bmj.39202.518484.80] [Cited by in Crossref: 46] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
234 Sheibani S, Cohen R, Kane S, Dubinsky M, Church JA, Mahadevan U. The Effect of Maternal Peripartum Anti-TNFα Use on Infant Immune Response. Dig Dis Sci 2016;61:1622-7. [DOI: 10.1007/s10620-015-3992-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
235 Golding A, Haque UJ, Giles JT. Rheumatoid arthritis and reproduction. Rheum Dis Clin North Am 2007;33:319-43, vi-vii. [PMID: 17499710 DOI: 10.1016/j.rdc.2007.01.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
236 Lockshin MD. Treating rheumatic diseases in pregnancy: dos and don'ts. Ann Rheum Dis 2006;65 Suppl 3:iii58-60. [PMID: 17038475 DOI: 10.1136/ard.2006.058420] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
237 Guerrero Vinsard D, Kane SV. Biologics and pregnancy: a clinician's guide to the management of IBD in pregnant women. Expert Rev Gastroenterol Hepatol 2021;15:633-41. [PMID: 33440996 DOI: 10.1080/17474124.2021.1876562] [Reference Citation Analysis]
238 Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006;4:1255-1258. [PMID: 17045211 DOI: 10.1016/j.cgh.2006.07.018] [Cited by in Crossref: 198] [Cited by in F6Publishing: 158] [Article Influence: 14.1] [Reference Citation Analysis]
239 Kammerlander H, Nielsen J, Kjeldsen J, Knudsen T, Gradel KO, Friedman S, Nørgård BM. Fecal Calprotectin During Pregnancy in Women With Moderate-Severe Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:839-48. [DOI: 10.1093/ibd/izx055] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
240 Komaki F, Komaki Y, Micic D, Ido A, Sakuraba A. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmun 2017;76:38-52. [PMID: 27913060 DOI: 10.1016/j.jaut.2016.11.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
241 Sauk J, Kane S. The use of medications for inflammatory bowel disease during pregnancy and nursing. Expert Opinion on Pharmacotherapy 2005;6:1833-9. [DOI: 10.1517/14656566.6.11.1833] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
242 Kroser J, Srinivasan R. Drug Therapy of Inflammatory Bowel Disease in Fertile Women. Am J Gastroenterology 2006;101:S633-9. [DOI: 10.1111/j.1572-0241.2006.00961.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
243 Orlando A, Mocciaro F, Civitavecchia G, Scimeca D, Cottone M. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. Digestive and Liver Disease 2008;40:S236-46. [DOI: 10.1016/s1590-8658(08)60532-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
244 Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol. 2013;19:2591-2602. [PMID: 23674866 DOI: 10.3748/wjg.v19.i17.2591] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 52] [Article Influence: 10.0] [Reference Citation Analysis]
245 Pentšuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: New insights into developmental toxicity testing of monoclonal antibodies. Birth Defect Res B 2009;86:328-44. [DOI: 10.1002/bdrb.20201] [Cited by in Crossref: 177] [Cited by in F6Publishing: 124] [Article Influence: 14.8] [Reference Citation Analysis]
246 Trivedi MK, Vaughn AR, Murase JE. Pustular psoriasis of pregnancy: current perspectives. Int J Womens Health 2018;10:109-15. [PMID: 29520163 DOI: 10.2147/IJWH.S125784] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 4.7] [Reference Citation Analysis]
247 Arai K, Takeuchi Y, Oishi C, Imawari M. The impact of disease activity of Crohn’s disease during pregnancy on fetal growth. Clin J Gastroenterol 2010;3:179-81. [DOI: 10.1007/s12328-010-0158-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
248 Horst S, Kane S. The use of biologic agents in pregnancy and breastfeeding. Gastroenterol Clin North Am 2014;43:495-508. [PMID: 25110255 DOI: 10.1016/j.gtc.2014.05.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
249 Berkhout A, Clark JE, Wen SC. In utero exposure to biologic disease-modifying anti-rheumatic drugs and effects to the infant: infectious complications, vaccine response, and safety of live vaccine administration. Expert Rev Vaccines 2019;18:495-504. [PMID: 30916600 DOI: 10.1080/14760584.2019.1599286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
250 Mountifield RE, Prosser R, Bampton P, Muller K, Andrews JM. Pregnancy and IBD treatment: this challenging interplay from a patients’ perspective. J Crohns Colitis. 2010;4:176-182. [PMID: 21122502 DOI: 10.1016/j.crohns.2009.10.001] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
251 Mountifield R, Bampton P, Prosser R, Muller K, Andrews JM. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis. 2009;15:720-725. [PMID: 19067431 DOI: 10.1002/ibd.20839] [Cited by in Crossref: 141] [Cited by in F6Publishing: 114] [Article Influence: 11.8] [Reference Citation Analysis]